- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06263959
A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B
February 14, 2024 updated by: Fujian Akeylink Biotechnology Co., Ltd.
A randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the safety and efficacy of GST-HG131 tablets in patients with chronic hepatitis B
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
45
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
- Recruiting
- The Fifth medical center of Chinese PLA General Hospital
-
Contact:
- Tang Yanan
- Phone Number: +8613585734994
- Email: annie_tyn@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Able to sign the informed consent form,and fully understand the test content, process and possible adverse reactions;
- Males and females aged 35-65 ,able to complete research in accordance with test plan requirements;
- Participants who have no childbearing plan in next year,and must agree to voluntarily use the contraceptive methods specified in the protocol from screening to 6 months after the last dose of the study;
- The weight of male patients shall not be less than 50 kg, and the weight of female patients is not less than 45 kg. Body mass index (BMI = weight (kg)/height 2 (m2)) in the range of 18.0~35.0 kg/m2;
- Participants who have received stable NA therapy for more than half a year and have maintained the NA regimen for ≥3 months prior to screening;
- At least two tests within 28 days of the screening period (more than 1 week apart) with HBV DNA lower than LLOQ;
- HBeAg negative, 100≤HBsAg quantitative ≤1500 IU/mL, serum ALT<1×ULN during screening;
- The normal or abnormal results of vital signs assessment, physical examination and 12-lead electrocardiogram during the screening period and baseline period have no clinical significance;
- Able to communicate well with clinical staff and complete the trial according to protocol requirements。
Exclusion Criteria:
- Participants with a history of allergy to the any ingredient or excipients of the drug under study;
- Patients who cannot tolerate venous blood collection and have a history of needle fainting or blood fainting;
- Patients with major trauma or major surgery within 3 months before screening; or plan to have surgery during the study;
- Blood donation or blood loss ≥400 mL within 3 months prior to screening, or received blood transfusion; or blood donation or blood loss ≥200 mL within 1 month prior to screening;
- A history of alcohol or drug abuse or dependence;
- Participants have participated in clinical trials of drugs or medical devices (except in vitro diagnostic reagents) within 3 months prior to administration;
- Use of any hepatitis B drug other than NUC within 1 year prior to administration;
- Participants with systemic use of immunosuppressants, immunomodulators (excluding interferon) and cytotoxic drugs within 6 months before screening; Or those who received live attenuated vaccine within 1 month before screening;
- Participants with clinically significant acute or chronic liver disease caused by non-HBV infection who were judged by the investigator to be unsuitable for the study;
- Participants with a history of cirrhosis (e.g., the subject had a histopathological examination of the liver and reported cirrhosis, or had an endoscopic examination indicating varicose esophagus and fundus veins);
- Participants with hepatitis B cirrhosis in the confirmed or suspected decompensated stage, including but not limited to: hepatic encephalopathy, hepatorenal syndrome, esophageal and fundus variceal bleeding, spleen enlargement, ascites, primary liver cancer, etc;
- Participants with malignancy or history of other malignancies within 5 years prior to screening (except cured basal cell or squamous cell carcinoma of the skin and carcinoma in situ of the cervix);
- The investigators determined the presence of impaired gastrointestinal function or gastrointestinal disease that might affect oral drug absorption, such as severe gastrointestinal disease (peptic ulcer, erosive or atrophic gastritis), partial gastrectomy, and gastrointestinal symptoms > grade 2 at the time of screening (e.g., nausea, vomiting, or diarrhea);
- Participants with suspected or confirmed acute infections within 2 weeks prior to randomization;
- Laboratory examination: platelet count < 90 x 10^9 / L; White blood cell count <3.0 x 10^9 / L; Neutrophils absolute value< 1.3 x 10^9 / L; Serum total bilirubin >2 x ULN. Albumin< 30 g/L; Creatinine clearance ≤ 60 mL/min or less; Prothrombin time international standardization ratio (INR) >1.5;
- Serum AFP (AFP) is greater than 50 ㎍ / L (or 50 ng/mL) or imaging suggest possible malignant liver placeholder;
- Hepatitis C antibody positive, treponema pallidum antibody positive and rapid plasma reagin test (RPR) positive,AIDS antigen/antibody positive;
- Breastfeeding women or those who have a positive pregnancy test at screening or baseline;
- The investigator believes that there are other subjects who are not suitable for participating in this trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Patiants on stable nucleos(t)ide analog (NA) therapy will be randomized 4:1 to receive repeat dose of either GST-HG131 (Dose 1) or placebo for 28 days.
|
GST-HG131 will be administered.
Placebo to match GST-HG131 will be administered.
|
Experimental: Cohort 2
Patiants on stable nucleos(t)ide analog (NA) therapy will be randomized 4:1 to receive repeat dose of either GST-HG131 (Dose 2) or placebo for 28 days.
|
GST-HG131 will be administered.
Placebo to match GST-HG131 will be administered.
|
Experimental: Cohort 3
Patiants on stable nucleos(t)ide analog (NA) therapy will be randomized 4:1 to receive repeat dose of either GST-HG131 (Dose 1 or 2) or placebo for 12 weeks.
|
GST-HG131 will be administered.
Placebo to match GST-HG131 will be administered.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in HBsAg levels
Time Frame: Baseline and up to 56 days(Cohort1 and 2) or 16 weeks(Cohort3)
|
Change from Baseline in HBsAg levels
|
Baseline and up to 56 days(Cohort1 and 2) or 16 weeks(Cohort3)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with adverse events (AEs), serious adverse events (SAEs), and withdrawals due to AEs
Time Frame: Up to 56 days(Cohort1 and 2) or 16 weeks(Cohort3)
|
Number of participants with adverse events (AEs), serious adverse events (SAEs), and withdrawals due to AEs
|
Up to 56 days(Cohort1 and 2) or 16 weeks(Cohort3)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 29, 2023
Primary Completion (Estimated)
September 1, 2024
Study Completion (Estimated)
November 1, 2024
Study Registration Dates
First Submitted
January 7, 2024
First Submitted That Met QC Criteria
February 14, 2024
First Posted (Actual)
February 16, 2024
Study Record Updates
Last Update Posted (Actual)
February 16, 2024
Last Update Submitted That Met QC Criteria
February 14, 2024
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Disease Attributes
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Chronic Disease
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B, Chronic
- Hepatitis, Chronic
Other Study ID Numbers
- GST-HG131-II-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hepatitis B
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Tongji HospitalGilead SciencesRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Changhai HospitalCompleted
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis b
-
Zhongshan Hospital Xiamen UniversityUnknownHealthy | Chronic Hepatitis B InfectionChina
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, Korea, Republic of
-
National Taiwan University HospitalChiayi Christian Hospital; E-DA Hospital; Taipei City Hospital; Taipei Tzu Chi... and other collaboratorsRecruitingChronic Hepatitis b | Hepatitis B ReactivationTaiwan
-
Mahidol UniversityUnknownChronic Hepatitis B, HBsAg, Hepatitis B VaccineThailand
Clinical Trials on GST-HG131
-
Fujian Cosunter Pharmaceutical Co. LtdUnknown
-
Fujian Akeylink Biotechnology Co., Ltd.Completed
-
Fujian Cosunter Pharmaceutical Co. LtdCompleted
-
Fujian Akeylink Biotechnology Co., Ltd.RecruitingChronic Hepatitis bChina
-
Fujian Cosunter Pharmaceutical Co. LtdRecruiting
-
Fujian Cosunter Pharmaceutical Co. LtdUnknown
-
Fujian Akeylink Biotechnology Co., Ltd.The First Hospital of Jilin UniversityRecruitingPharmacokinetics | Food Affect | Single Ascending Dose | Maximum Applicable DoseChina
-
Baylor College of MedicineGeorge Washington University; Children's National Research InstituteCompletedHookworm Infection | Hookworm DiseaseUnited States
-
Fujian Cosunter Pharmaceutical Co. LtdUnknownSolid Tumor | C-Met Mutation-Related TumorsChina
-
Fujian Akeylink Biotechnology Co., Ltd.CompletedPharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Liver FunctionCOVID-19 PneumoniaChina